Get started
Author

Alens Valentin

ORCID: 0009-0003-4348-4527
Observed ORCID: 0009-0003-4348-4527
OpenAlex ID: A5031019995
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al. · Clinical Cancer Research · 15
Ablating UNG activity in a mouse model inhibits colorectal cancer growth by increasing tumor immunogenicity
2025 · Eric S. Christenson, Brandon E. Smith, et al. · JCI Insight · 3
PDF
Abstract A071: Deep learning enabled 3D multi-omic analysis reveals molecular signatures of heterogeneous response to chemotherapy in pancreatic cancer
2026 · André Forjaz, Hengameh Mojdeganlou, et al. · Cancer Research
Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer
2026 · André Forjaz, Hengameh Mojdeganlou, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Supplementary Table 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al. · Clinical Cancer Research
PDF
Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
PDF
Supplementary Table 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Figure 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
PDF
Supplementary Table 7 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 8 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Figure 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
PDF
1215 Spatial profiling identifies antigen-presenting CAFs as potential mediators of response to neoadjuvant immunotherapy in hepatocellular carcinoma
2025 · Shuming Zhang, Nick Sun, et al. · Regular and Young Investigator Award Abstracts
PDF
Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
PDF
Supplementary Table 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 7 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Table 8 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
PDF
Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al.
PDF
Works count: 31
Citation count: 18
H-index: 2
I10-index: 1
Year
Topic
Type